5th most common cancer in europe and 6th most comon in the US
430,000 new bladder cancer cases diagnosed in 2012 worldwide
3 times more common in men compared to women
highest lifetime treatment costs per patient out of all cancers
Bladder EpiCheck is Nucleix’s first product that includes a panel of 15 DNA methylation biomarkers for detection of bladder cancer.
Bladder EpiCheck is expected to be launched at Q1 2017 in the EU, followed by other markets.
Bladder EpiCheck is not currently approved for clinical use.
Bladder EpiCheck – Performance
EpiCheck has a very high ability to correctly identify patients with cancer
EpiCheck has a very high ability to correctly identify patients without cancer
EpiCheck negative predictive value means 97% probability of being a true negative**
* Results are based on a clinical evaluation study with 222 bladder cancer patients post-treatment that came for recurrence monitoring. Performed in collaboration with Meir Medical Center, Israel
** Calculated assuming 17.6% prevalence of disease recurrence (as in this cohort)